Peanut Allergy

Background

Peanut allergy is an immune-mediated condition affecting a significant portion of the population, particularly children. It is estimated to affect approximately 5% to 8% of children in the United States, and its prevalence has been consistently increasing globally over the past two decades, including in European countries and Australia.^{[1], [2]}This condition is a complex disease influenced by both genetic predispositions and environmental factors.^[2]Individuals with peanut allergy can experience severe allergic reactions, including life-threatening anaphylaxis.^[2] Twin studies and familial aggregation research have indicated a strong genetic component, with heritability estimates ranging from 15% to 82%, and some studies suggesting figures around 80%.^{[1], [2], [3]}

Biological Basis

Peanut allergy is primarily an immunoglobulin E (IgE)-mediated hypersensitivity reaction to peanut proteins.^[1]The genetic underpinnings of peanut allergy have been a focus of research, with several loci identified. Genetic variants within the Human Leukocyte Antigen (HLA) Class II genes, particularlyHLA-DQB1 (e.g., DQB102 and DQB106:03P), HLA-DRB1, HLA-DRA, and HLA-DPB1, have been consistently associated with susceptibility to peanut allergy.^{[1], [2], [3], [4], [5]}For instance, specific amino acid polymorphisms inHLA-DRB1 and variants in HLA-DRA may influence HLA protein function and expression, affecting the binding and presentation of peanut allergens.^[3]Beyond the HLA region, other genes linked to peanut allergy includeSTAT6, CD14, and FLG (filaggrin).^{[1], [6], [7]} Loss-of-function mutations in the epidermal barrier gene FLG are considered a significant risk factor, potentially by compromising the skin barrier and allowing increased allergen penetration and sensitization.^{[2], [3], [8]} Recent genome-wide association studies (GWAS) have also identified the SERPINBgene cluster as a susceptibility locus for food allergy, including peanut allergy.^[2] and provided evidence of epigenetic mediation in US children.^[3]Furthermore, research has explored maternal genetic effects and parent-of-origin effects, with a suggestive parent-of-origin effect identified for peanut allergy in theADGB gene.^[1]

Clinical Relevance

Accurate identification of peanut allergy is crucial for patient management and safety. Diagnosis typically involves assessing clinical allergic reactions, often confirmed through skin prick tests (SPT) and of food-specific IgE levels.^[3] Standardized double-blind, placebo-controlled oral food challenges are considered the gold standard for diagnosis.^[9] Studies have shown significant differences in peanut-specific IgG levels between peanut-allergic individuals and their peanut-tolerant siblings, which appear to be independent of HLA class II variations.^[7]Understanding the genetic factors and biological pathways involved in peanut allergy can contribute to improved diagnostic tools and potentially personalized management strategies.

Social Importance

Peanut allergy represents a significant public health challenge globally.^[1] Beyond the immediate health risks, it carries a considerable economic burden in the United States, impacting healthcare costs and daily lives.^{[10], [11]} The condition also has a substantial psychosocial impact on affected children, adolescents, and their families, affecting quality of life, social activities, and mental well-being.^{[12], [13]}Research into the genetic and biological basis of peanut allergy is vital for developing effective prevention strategies, treatments, and improving the overall quality of life for those affected.

Methodological and Statistical Constraints

Studies on peanut allergy are often limited by sample size and statistical power, which can impact the reliability and generalizability of findings. For instance, some research acknowledges being underpowered at a genome-wide level for both any food allergy and its specific subtypes, necessitating cautious interpretation of identified associations. This constraint particularly affects the detection of rare genetic variants or common variants with subtle effects, requiring substantially larger cohorts for comprehensive analysis.^[3]While some studies represent the largest genome-wide association studies (GWAS) for food allergy to date, the sample sizes remain relatively small for complex genetic traits, often leading to power sufficient only for detecting loci with larger effect sizes.^[2] Furthermore, the replication of findings is crucial for strengthening evidence. Although initial GWAS results may be replicated in independent sample sets from the same study cohort, broader validation through additional replications in diverse, independent populations is often needed to confirm associations and ensure their robustness. Without extensive external replication, the generalizability of specific genetic associations to wider populations remains a consideration, potentially limiting the confidence in their widespread applicability.^[3]

Phenotypic Definition and Generalizability

Challenges in defining peanut allergy phenotypes and the generalizability of findings across diverse populations present significant limitations. Genetic associations, such as those involvingrs7192 and rs9275596 , have shown different patterns across ancestries, being significant in participants of European ancestry but not in non-European groups.^[3] However, drawing firm conclusions about population-specific effects is often hindered by limited sample sizes within non-European cohorts, impeding a complete understanding of genetic architecture across different ancestral backgrounds.^[3] Phenotype definition also introduces variability. Allergic status may be determined using specific IgE cutoffs and skin prick tests, but the availability of complete clinical reaction histories can be inconsistent, leading to uncertain diagnoses, particularly for parents.^[3] The use of strict phenotype definitions, while enhancing diagnostic accuracy, can also make it challenging to recruit large patient numbers, especially when gold-standard methods like oral food challenges are not universally performed.^[2]For epigenetic studies, the examination of methylation patterns in blood offers insights into a systemic condition like food allergy; however, the dynamic and tissue-specific nature of methylation suggests that single-tissue, single-time-point measurements may not fully capture the complex, temporal relationship between epigenetic changes and allergy risk.^[3]

Unaccounted Factors and Remaining Knowledge Gaps

The genetic basis of peanut allergy, like many complex traits, is characterized by “missing heritability,” indicating that identified genetic variants explain only a fraction of the observed heritability.^[1] This discrepancy between heritability estimates from GWAS and those derived from family or twin studies may stem from various factors, including the underestimation of common environmental contributions, complex gene-environment interactions, or model misspecification in genetic analyses.^[2] Such interactions mean that genetic predispositions may only manifest under specific environmental conditions, which are often not fully captured or accounted for in current study designs.

Furthermore, studies have historically focused primarily on individual genotypes, often without considering critical environmental influences such as maternal genetic effects during pregnancy.^[1] These unmeasured or unmodeled environmental factors, alongside the inherent complexity of epigenetic regulation and potential batch effects in data processing, can confound findings and obscure true genetic or epigenetic associations.^[3]Consequently, despite advancements, the underlying causes and comprehensive biological mechanisms of food allergy remain incompletely understood, necessitating further investigation into functional mechanisms and the interplay of diverse genetic and environmental factors.^[1]

Variants

Genetic variations play a crucial role in an individual’s susceptibility to peanut allergy, influencing immune responses and cellular pathways. A key region implicated in peanut allergy is the Major Histocompatibility Complex (MHC) on chromosome 6, which includes theHLA-DQB1 and HLA-DQA2 genes. The variant rs9275596 , located between these two genes, has shown a significant association with peanut allergy.^[3] These HLA genes encode proteins essential for presenting antigens, like those from peanuts, to T-cells, thereby initiating the immune cascade that leads to allergic reactions. Specific HLA-DQB1 alleles, such as HLA-DQB1*02 and DQB1*06:03P, are also associated with peanut allergy, highlighting the importance of this region in shaping the immune system’s recognition of allergens.^[5] The presence of these variants can alter the binding specificity of HLA proteins, influencing whether the immune system identifies peanut components as harmful.

Beyond the HLA region, other variants contribute to the complex genetics of peanut allergy by affecting diverse cellular functions and immune cell signaling. For instance,rs72827854 in the SKAP1 gene is relevant because SKAP1 encodes an adapter protein critical for T-cell receptor signaling and the activation of lymphocytes, key players in allergic responses. Similarly, rs744597 near ARHGAP24 may impact immune cell function, as ARHGAP24 regulates Rho GTPases, which are vital for cell shape, motility, and adhesion in immune cells.^[2] Variants like rs115218289 in ITGA6, which encodes an integrin involved in cell adhesion and migration, could influence the integrity of epithelial barriers or the movement of immune cells to sites of allergic inflammation. The variant rs17664036 within the KIZ gene, involved in centrosome organization, might indirectly affect the development or function of immune cells.

Further genetic contributions to peanut allergy risk can arise from variants in genes involved in tissue remodeling, inflammation, and non-coding RNA regulation. The variantrs144897250 , located near MMP12 and BOLA3P1, is of interest because MMP12 (Matrix Metallopeptidase 12) is an enzyme that breaks down components of the extracellular matrix, playing a role in inflammation and tissue repair, which are processes dysregulated in allergic conditions. Variants like rs7936434 in the EMSY - LINC02757 region and rs862942 in LINC02306 may influence gene expression through their association with long non-coding RNAs, which can regulate various cellular processes. While the specific functions of pseudogenes like MTCO3P1, RNU6-92P, ST13P7, and RN7SKP48 are often less direct, variants like rs78048444 in these regions could still have regulatory effects on nearby functional genes or serve as markers for other causal variants. Lastly, rs523865 in ANGPT4 could potentially impact vascular changes associated with allergic inflammation.

Key Variants

RS ID	Gene	Related Traits
rs9275596	MTCO3P1 - HLA-DQB3	kidney disease IGA glomerulonephritis peanut allergy omega-6 polyunsaturated fatty acid
rs17664036	KIZ	peanut allergy
rs115218289	ITGA6	peanut allergy food allergy
rs523865	ANGPT4	peanut allergy food allergy
rs7936434	EMSY - LINC02757	peanut allergy food allergy type 1 diabetes mellitus eosinophil count Eczematoid dermatitis
rs144897250	MMP12 - BOLA3P1	peanut allergy blood protein amount
rs78048444	RNU6-92P - ST13P7	peanut allergy food allergy
rs744597	RN7SKP48 - ARHGAP24	peanut allergy
rs862942	LINC02306	peanut allergy vaginal microbiome
rs72827854	SKAP1	peanut allergy

Defining Peanut Allergy and its Core Diagnostic Framework

Peanut allergy (PN) is a specific manifestation of food allergy (FA), characterized by an adverse immunological reaction to peanut proteins upon ingestion.^[2]A precise definition of peanut allergy necessitates both a compelling clinical history of reactions and objective evidence of sensitization.^[2] The conceptual framework for understanding this condition differentiates between mere sensitization—the presence of specific antibodies or a positive skin test—and a true allergic reaction, which involves the manifestation of clinical symptoms.^[3] Operational definitions for research purposes rigorously combine a convincing history of a clinical allergic reaction to peanuts with specific immunological findings, aiming to accurately phenotype affected individuals.^[3]

Diagnostic Criteria and Approaches

The definitive diagnostic criterion for peanut allergy is the Double-Blind, Placebo-Controlled Oral Food Challenge (DBPCFC), which is widely considered the gold standard.^[9] These challenges involve the controlled administration of the suspected allergen in a supervised medical environment, enabling an objective assessment of any elicited symptoms.^[2] However, for individuals with a history of immediate and severe allergic reactions and high levels of specific sensitization, an OFC may be contraindicated due to the inherent risk, with diagnosis then relying on a strong clinical history combined with specific laboratory findings.^[2] Objective evidence of sensitization is a critical component of diagnosis, primarily assessed through biomarkers like food-specific IgE levels and Skin Prick Tests (SPT).^[3] For SPT, a positive result is typically defined by a mean weal diameter (MWD) of 3 mm or greater.^[3] For food-specific IgE, common diagnostic thresholds include ≥ 0.10 kU L−1 or ≥ 0.35 kU L−1, although research studies may explore alternative cut-off values, such as those correlating with a 95% positive predictive value.^[3] Normal controls in studies are specifically defined as children exhibiting neither a history of clinical allergic reactions nor any evidence of sensitization to common food allergens, including peanuts.^[3]

Classification Systems and Associated Terminology

Peanut allergy is classified within broader nosological systems of food allergies, which encompass reactions to other common allergens such as egg, cow’s milk, soy, wheat, walnut, fish, shellfish, and sesame seed.^[3]The term “any FA” is utilized to categorize individuals who exhibit an allergy to at least one of these nine frequently implicated foods.^[3] While the primary classification approach presented is categorical (identifying individuals as allergic or non-allergic), the acknowledgement of severe reactions implies a dimensional aspect related to severity, which influences diagnostic pathways and management strategies.^[2] The concept of sensitization, distinct from a full-blown allergic reaction, refers specifically to the presence of IgE antibodies or a positive SPT without the definitive occurrence of clinical symptoms.^[3]Key terminology also extends to genetic factors that confer susceptibility to peanut allergy. These include theHLA-DQB1locus, which has been consistently associated with peanut allergy across various studies.^[2] and the SERPINB gene cluster, identified as a susceptibility locus.^[2] Other genes such as filaggrin, STAT6, CD14, CTNNA3, and RBFOX1have also been investigated for their roles in food and peanut allergy.^[2]The ongoing evolution in understanding peanut allergy phenotypes underscores the critical importance of standardized vocabularies for both clinical practice and genetic research.^[2]

Clinical Assessment and Oral Food Challenges

Diagnosis of peanut allergy typically commences with a comprehensive clinical evaluation, including a detailed patient history of reactions following peanut ingestion and a physical examination. The gold standard for confirming peanut allergy is the double-blind, placebo-controlled oral food challenge (DBPCOFC), which involves the supervised administration of the allergen in a controlled clinical setting to elicit a reaction.^[2] This functional test offers high diagnostic accuracy, distinguishing true allergic reactions from food intolerances or other non-allergic conditions. However, DBPCOFCs are resource-intensive and carry an inherent risk of inducing severe allergic reactions, making them contraindicated for individuals with a convincing history of immediate and severe anaphylactic responses to peanuts.^[3] Such challenges are typically performed in an inpatient hospital setting under close medical supervision.^[3]

Immunological Biomarkers and Skin Testing

Complementing clinical history, laboratory and screening methods play a crucial role in the diagnostic workup for peanut allergy. Food-specific immunoglobulin E (IgE) blood tests measure circulating antibodies against peanut allergens, with levels exceeding 0.35 kU/L often indicative of sensitization.^[2] Skin prick tests (SPT) are another common screening tool, where a positive result is typically defined by a wheal diameter of at least 3 mm greater than the negative control, or sometimes by a wheal of 5 mm or greater, or above the 95th percentile.^[3]While both IgE levels and SPT provide evidence of sensitization, they do not always correlate directly with clinical reactivity. Therefore, these molecular markers necessitate careful interpretation in conjunction with the patient’s clinical history and, if appropriate, subsequent oral food challenges to confirm a diagnosis and differentiate between sensitization and clinical allergy.

Genetic Predisposition and Molecular Markers

Emerging research highlights the genetic underpinnings of peanut allergy, with genome-wide association studies (GWAS) identifying specific susceptibility loci and evidence of epigenetic mediation.^[3] Genetic variants within the SERPINBgene cluster have been associated with an increased risk for food allergy.^[3] Polymorphisms in HLA class II genes, including HLA-DRB1, DQB1, and DPB1, show genotypic associations with peanut allergy, withHLA-DQB1*02 and DQB1*06:03P specifically linked to the condition.^[4] although some studies have reported a lack of association with HLA class II alleles.^[3] Additionally, loss-of-function variants in the FILAGGRINgene are recognized as significant risk factors for peanut allergy, an association that persists irrespective of variations in diagnostic criteria or asthma status.^[8] Further genetic markers include polymorphisms in STAT6 and specific genetic variants of CD14that are associated with peanut allergy and elevated IgE levels.^[6] Copy number variations in CTNNA3 and RBFOX1have also been associated with pediatric food allergy.^[3] While not yet routine diagnostic tools, these genetic and molecular markers, such as rs7192 and rs9275596 , offer valuable insights into disease mechanisms and hold significant potential for informing future predictive strategies, personalized prevention, and targeted treatment approaches for peanut allergy.^[3]

Biological Background

Peanut allergy is a serious and potentially life-threatening condition characterized by an adverse immune response to peanut proteins. It is recognized as an immunoglobulin E (IgE)-mediated hypersensitivity reaction, where the body’s immune system mistakenly identifies peanut proteins as harmful.^[1] The underlying biological mechanisms involve a complex interplay of genetic predispositions, molecular signaling pathways, disruptions in tissue barrier functions, and the activation of specific immune cells and biomolecules.

Immune System Dysregulation and Allergen Recognition

Peanut allergy is fundamentally an IgE-mediated hypersensitivity, meaning the immune system overreacts to peanut proteins by producing specific IgE antibodies.^[1] This process involves the recognition of peanut allergens by antigen-presenting cells (APCs), which then process and present these fragments to T-helper cells, initiating a cascade that leads to B cells producing large amounts of IgE. Key biomolecules in this recognition process include HLA (Human Leucocyte Antigen) class II molecules, such as HLA-DRB1, HLA-DQB1 (*02 and *06:03P), and HLA-DRA, which are critical for binding and presenting allergen peptides to T cells.^[2]Amino acid polymorphisms inHLA-DRB1, particularly at position 71 and other positions like 13, 70, and 74, can alter the peptide-binding groove, affecting the specificity of antigen interaction and presentation.^[3] Genetic variants within HLAgenes, such as the missense single nucleotide polymorphism (SNP)rs7192 in HLA-DRA, can directly impact the function or expression of HLA-DRA protein, thereby influencing how HLA molecules bind to peanut allergens.^[3] This SNP has been linked to HLA-DRA gene expression in various tissues, including lymphoblastoid cell lines and adipose tissue, which are relevant to APC function throughout the body.^[3] Furthermore, genes like STAT6 and CD14 play roles in this immunological regulation; a polymorphism in STAT6is associated with risk for nut allergy, and genetic variants ofCD14are linked to peanut allergy and elevated IgE levels, highlighting their involvement in the molecular and cellular pathways that drive allergic responses.^[6]

Epithelial Barrier Function and Sensitization

The integrity of epithelial barriers, particularly in the skin and gastrointestinal tract, is crucial in preventing allergen entry and subsequent sensitization. A compromised barrier can allow allergens to penetrate more easily, initiating an immune response even at low exposure levels. Loss-of-function variants in the FLG(Filaggrin) gene are a significant risk factor for peanut allergy, asFLG is essential for maintaining the skin barrier.^[2] These FLGdefects lead to increased allergen penetration and sensitization to peanut, forming a basis for the “atopic march,” where skin barrier dysfunction contributes to the development of various allergic phenotypes.^[2] Beyond the skin, other epithelial tissues are also critical. The SERPINBgene cluster has been identified as a susceptibility locus for food allergy, and its genes are highly expressed in the esophagus, suggesting a role in the gastrointestinal barrier.^[2] Variants within this cluster are associated with altered SERPINB10 expression in leukocytes, indicating broader immunological and barrier-related functions.^[2] Both FLG and SERPINBgenes underscore the importance of robust epithelial barrier function and its immunological regulation in preventing the initial sensitization phase of peanut allergy.^[2]

Genetic Susceptibility and Regulatory Mechanisms

Peanut allergy is a complex trait with a strong genetic component, demonstrated by familial aggregation and twin studies that estimate its heritability to range significantly, from 15% to 82%.^[3]Genome-wide association studies (GWAS) have been instrumental in identifying specific genetic loci associated with food allergy risk. These studies have pinpointed theSERPINB gene cluster, the C11orf30/LRRC32 locus, and the human leukocyte antigen (HLA) region as susceptibility loci.^[2] Notably, the association with the HLAlocus is specific to peanut allergy, while other identified loci may confer risk for food allergy more generally.^[2] Specific genetic variants, such as rs12123821 , rs11949166 , and rs12964116 , have also been associated with food allergy accompanied by eczema.^[2]Beyond direct genetic variants, regulatory elements and epigenetic modifications are increasingly recognized for their role in modulating gene expression and influencing allergy development. Research indicates evidence of epigenetic mediation in peanut allergy, suggesting that environmental factors can alter gene activity without changing the underlying DNA sequence.^[3]Furthermore, the genetic landscape of food allergy is complicated by maternal genetic effects and potential parent-of-origin effects, where the inheritance pattern of an allele from either parent can influence disease risk.^[1]These complex genetic and epigenetic interactions collectively contribute to an individual’s predisposition to peanut allergy, highlighting a multifaceted regulatory network.

Genetic Risk Stratification and Early Identification

The identification of specific genetic loci associated with peanut allergy (PA) offers critical avenues for risk stratification and early identification. Genome-wide association studies (GWAS) have pinpointed regions such as theSERPINB gene cluster and specific HLA Class II alleles, including HLA-DQB1*02 and HLA-DQB1*06:03P, as susceptibility loci.^[2] These genetic markers could serve as powerful tools to identify individuals, particularly children, who are at a higher genetic predisposition for developing PA, even prior to overt clinical symptoms or sensitization.^[3] Furthermore, loss-of-function variants in the filaggrin (FLG) gene represent a significant risk factor for PA, with this association consistently observed across different diagnostic criteria and asthma statuses.^[8] Incorporating such genetic insights into diagnostic algorithms could enhance the accuracy of risk assessment beyond traditional methods like skin prick tests or food-specific IgE levels, particularly in cases where clinical presentation is ambiguous, or to prioritize individuals for more definitive, but resource-intensive, oral food challenges.^[3] This genetic "" provides a foundation for more precise patient stratification.

Prognostic Indicators and Disease Trajectory

Genetic markers associated with peanut allergy (PA) hold prognostic value by offering insights into the likely course and long-term implications of the condition. While direct links between specific genetic variants and treatment response require further research, understanding an individual’s genetic predisposition can inform predictions about disease persistence or severity.^[3] For instance, the presence of certain HLA alleles or FLG mutations might correlate with a more persistent or severe phenotype of PA, guiding clinicians in setting realistic expectations and developing long-term management plans.^[2] The research on epigenetic mediation, alongside identified genetic loci, suggests a complex interplay that could influence the progression of PA.^[3]These genetic “measurements” could help differentiate between transient allergic sensitization and true, persistent clinical allergy, thereby refining prognostic counseling for families and potentially reducing unnecessary dietary restrictions if a lower risk of persistence is indicated.^[3] Such advancements could transform how clinicians monitor and anticipate the trajectory of PA in affected individuals.

Informing Personalized Management and Prevention

The identification of peanut allergy (PA)-specific genetic loci, including theSERPINB gene cluster and HLA variants, offers a foundation for developing personalized medicine approaches and targeted prevention strategies.^[2] By understanding the genetic underpinnings, clinicians may be able to tailor early intervention programs for high-risk infants, potentially through specific dietary introductions or environmental modifications, moving beyond general population guidelines.^[3] This personalized genetic "" could lead to more effective prevention, reducing the burden of PA.

Furthermore, these genetic insights could eventually inform treatment selection, although this area requires substantial further investigation. While current treatments primarily focus on avoidance and emergency management, genetic profiles might one day guide the choice of immunotherapies or novel pharmacological agents, optimizing their efficacy and minimizing adverse effects for genetically predisposed individuals.^[3]The goal is to move towards precision allergy medicine, where an individual’s genetic makeup dictates their unique management pathway.

Interplay with Comorbidities and Atopic Phenotypes

Peanut allergy (PA) frequently co-occurs with other atopic conditions, and genetic studies illuminate these important comorbidities and overlapping phenotypes. Loss-of-function mutations in thefilaggrin (FLG) gene, a known risk factor for PA, are also recognized to predispose individuals to phenotypes involved in the “atopic march,” such as eczema and asthma.^[2] This genetic link highlights PA not as an isolated condition, but often as part of a broader allergic predisposition, influencing patient management across multiple allergic disorders.^[8]The strong association between food allergy and eczema, as evidenced by studies that specifically analyzed “food allergy plus eczema” as a phenotype, underscores the clinical importance of considering these conditions together.^[2] Genetic “measurements” can therefore help clinicians identify individuals at high risk for developing not only PA but also a constellation of allergic diseases, enabling a more holistic and integrated approach to patient care, including early screening and management of related atopic conditions from infancy through adolescence.^[2]

Global and Regional Prevalence Patterns

Population studies reveal a significant and increasing burden of peanut allergy globally. In the United States, food allergy, including peanut allergy, affects an estimated 2–10% of children, a figure that has risen considerably over the past two decades, transforming it into a major public health concern due to its potential severity and associated economic impact.^[3] Comprehensive systematic reviews and meta-analyses have further detailed the prevalence of common food allergies across Europe, highlighting regional variations and providing crucial insights into the geographical distribution of this condition.^[14]These epidemiological investigations often utilize methods like population-based sampling and predetermined challenge criteria, such as those employed in studies assessing IgE-mediated food allergy in infants, to ensure diagnostic accuracy and comparability across diverse populations.^[15]Longitudinal studies in regions like the UK have also tracked time trends in allergic disorders, demonstrating the evolving landscape of conditions like peanut allergy over time.^[11]

Genetic Susceptibility and Population-Specific Effects

Large-scale cohort and biobank studies have been instrumental in unraveling the genetic underpinnings of peanut allergy, identifying specific loci and contributing to our understanding of population-level susceptibility. A genome-wide association study (GWAS) involving 2,197 participants of European ancestry identified peanut allergy-specific loci within theHLA-DR and -DQ gene region (6p21.32), tagged by rs7192 and rs9275596 , with these associations subsequently replicated in an independent European ancestry cohort.^[3]Further research indicates that these single-nucleotide polymorphisms (SNPs) are linked to differential DNA methylation levels, suggesting that epigenetic mechanisms involvingHLA-DQB1 and HLA-DRB1genes may partially mediate the genetic risk for peanut allergy.^[3] Beyond the HLA region, other genetic factors have been implicated, including loss-of-function variants in the filaggringene, which represent a significant risk factor for peanut allergy, and associations withHLA-DQB1*02 and DQB1*06:03P alleles.^[8]Studies like the German Genetics of Food Allergy Study (GOFA), the Heinz Nixdorf Recall Study (HNR), the Study of Health in Pomerania (SHIP), and the Chicago Food Allergy Study (CFA) are examples of major population cohorts that have facilitated such genome-wide investigations, contributing to a broader understanding of genetic predisposition in different populations.^[2]

Methodological Approaches in Population Studies

The robust of peanut allergy in population studies relies on a variety of methodological approaches, ranging from extensive questionnaires to advanced genetic analyses. Many studies, such as the Chicago Food Allergy Study, employ comprehensive protocols that include detailed questionnaire interviews to gather information on home environment, diet, lifestyle, and medical history, alongside clinical evaluations involving physical measurements and allergy skin prick testing (SPT).^[3]The gold standard for diagnosis, the double-blind, placebo-controlled oral food challenge (DBPCFC), is often incorporated into study designs to confirm allergy status with high accuracy, ensuring reliable case ascertainment in epidemiological research.^[3] Genetic investigations frequently utilize family-based designs, including twin studies and case-parent trio studies, to explore familial aggregation, heritability, and parent-of-origin effects.^[16] Researchers carefully consider sample sizes, representativeness, and potential confounders, adjusting for factors such as age, gender, and population stratification (e.g., using principal components for non-European subjects) to enhance the generalizability and validity of their findings across diverse populations.^[3]

Frequently Asked Questions About Peanut Allergy

These questions address the most important and specific aspects of peanut allergy based on current genetic research.

---

1. My sibling is allergic, but I’m not. Why the difference?

Even with a strong genetic component, estimated up to 80% heritability, peanut allergy is complex. You and your sibling share many genes, but also have genetic differences. Specific variations in genes likeHLA-DQB1 or FLGcan increase susceptibility, and you might not have inherited the same risk variants as your sibling. Environmental factors also play a role, making each individual’s allergy risk unique.

2. Is a DNA test useful to know my allergy risk?

Understanding your genetic risk for peanut allergy is becoming more feasible. Research has identified several genes, such as those in theHLA region, STAT6, and FLG, that are consistently linked to susceptibility. A DNA test could identify if you carry some of these risk variants, helping to estimate your predisposition. However, genetic tests alone don’t give a definitive diagnosis, as environmental factors also contribute.

3. If my family has allergies, can I prevent my kids’ risk?

Peanut allergy has a significant genetic basis, meaning a family history does increase your children’s risk. Heritability estimates can be quite high, around 80% in some studies. While genetics play a big role, it’s a complex interaction with environmental factors. Currently, there isn’t a guaranteed way to prevent it entirely based on genetics, but understanding these predispositions can guide future prevention strategies.

4. Could my skin problems make me more likely to have this allergy?

Yes, there’s a strong connection! If you have certain variations, particularly “loss-of-function” mutations, in a gene called FLG(filaggrin), your skin barrier can be compromised. This weakened barrier may allow peanut allergens to penetrate the skin more easily, leading to increased sensitization and a higher risk of developing a peanut allergy.

5. Why can some people eat peanuts without any problem?

It comes down to a combination of genetic predisposition and environmental factors. Some individuals have genetic variations that protect them, or they simply haven’t inherited the specific risk variants found in genes like HLA-DQB1 or SERPINBthat are linked to peanut allergy susceptibility. Their immune system doesn’t mount the specific IgE-mediated hypersensitivity reaction to peanut proteins that allergic individuals do.

6. Will my children definitely inherit my peanut allergy?

Not necessarily “definitely.” While peanut allergy has a strong genetic component, with heritability estimates sometimes reaching 80%, it’s not simply passed down like a single trait. It’s a complex disease influenced by many genes and environmental factors. For instance, research suggests parent-of-origin effects for genes likeADGB, meaning the risk can depend on which parent a gene variant is inherited from.

7. Why do doctors need so many tests to diagnose peanut allergy?

Peanut allergy diagnosis is complex because it’s crucial to be accurate due to the potential for severe reactions. Doctors typically assess your clinical symptoms, perform skin prick tests (SPT), and measure specific IgE levels in your blood. The gold standard, a double-blind, placebo-controlled oral food challenge, is often needed to confirm the diagnosis, as genetics and environmental factors make individual responses highly variable.

8. Why are more kids getting peanut allergy nowadays?

The prevalence of peanut allergy has indeed been increasing globally over the past two decades. This rise is thought to be due to a complex interplay of both genetic predispositions and changing environmental factors. While specific reasons for the increase are still being researched, it highlights the dynamic nature of this immune-mediated condition.

9. Could a genetic test help manage my allergy better?

Potentially, yes. Understanding the specific genetic factors involved in your peanut allergy could lead to more personalized management strategies. Researchers are actively working to use this genetic information to develop improved diagnostic tools and potentially even targeted treatments, moving beyond general advice to approaches tailored to your unique genetic profile.

10. How does my body become ‘allergic’ to peanuts?

Your body becomes allergic through a process called sensitization, where your immune system mistakenly identifies peanut proteins as a threat. This triggers an IgE-mediated hypersensitivity reaction. Genetic factors play a crucial role, with genes like those in the HLA region influencing how your immune cells bind and present peanut allergens, effectively “teaching” your body to react defensively.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Liu, X. et al. “Genome-wide association study of maternal genetic effects and parent-of-origin effects on food allergy.”Medicine (Baltimore) 97 (2018): e9772.

[2] Marenholz, I. et al. “Genome-wide association study identifies the SERPINB gene cluster as a susceptibility locus for food allergy.”Nat Commun 8 (2017): 1056.

[3] Hong, X. et al. “Genome-wide association study identifies peanut allergy-specific loci and evidence of epigenetic mediation in US children.”Nat Commun 6 (2015): 6304.

[4] Howell, W. M. et al. “HLA class II DRB1, DQB1 and DPB1 genotypic associations with peanut allergy: evidence from a family-based and case-control study.”Clin Exp Allergy 28 (1998): 156–62.

[5] Madore, A. M. et al. “HLA-DQB102 and DQB106:03P are associated with peanut allergy.”Eur J Hum Genet 21 (2013): 1181–4.

[6] Amoli, M. M. et al. “Polymorphism in the STAT6 gene encodes risk for nut allergy.”Genes Immun 3 (2002): 220–4.

[7] Dreskin, S. C. et al. “Association of genetic variants of CD14 with peanut allergy and elevated IgE levels in peanut allergic individuals.”Ann Allergy Asthma Immunol 106 (2011): 170–2.

[8] Brown, S. J. et al. “Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy.”J Allergy Clin Immunol 127 (2011): 661–7.

[9] Sampson, H. A. et al. “Standardizing double-blind, placebo-controlled oral food challenges: American academy of allergy, asthma & immunology-European academy of allergy and clinical immunology PRACTALL consensus report.”J Allergy Clin Immunol 130 (2012): 1260–1274.

[10] Patel, D. A., et al. “Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States.” J Allergy Clin Immunol, vol. 128, no. 1, 2011, pp. 110–115.e5.

[11] Gupta, R., et al. “The Economic Impact of Childhood Food Allergy in the United States.”JAMA Pediatr, 2013.

[12] Cohen, B. L., et al. “Development of a questionnaire to measure quality of life in families with a child with food allergy.”J Allergy Clin Immunol, vol. 114, no. 5, 2004, pp. 1159–63.

[13] Cummings, A. J., et al. “The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review.”Allergy, vol. 65, no. 8, 2010, pp. 933–45.

[14] Nwaru, Bright I., et al. “Prevalence of common food allergies in Europe: a systematic review and meta-analysis.” Allergy, vol. 69, no. 8, 2014, pp. 992-1007.

[15] Osborne, Nicholas J., et al. “Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants.”Journal of Allergy and Clinical Immunology, vol. 127, no. 3, 2011, pp. 668-676.e1-2.

[16] Sicherer, S. H., et al. “Genetics of peanut allergy: a twin study.”J Allergy Clin Immunol, vol. 106, no. 1 Pt 1, 2000, pp. 53–56.